India coronary stent market set for 4% CAGR growth during 2024-2033, forecasts GlobalData

New Delhi: As coronary artery disease (CAD) cases continue to rise in India, the demand for advanced treatment options such as drug-eluting stents (DES) is gaining momentum. Against this backdrop, India coronary drug eluting stent market is expected to grow at a compound annual growth rate (CAGR) of 4% from 2024 to 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report “Coronary Stents Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033” reveals that India’s coronary drug eluting stent market accounts for around 32% of the Asia-Pacific market in 2024.

Sahajanand Medical Technologies (SMT), an India-based developer and manufacturer of minimally invasive coronary stent systems, has recently received approval from the Australian Therapeutic Goods Administration (TGA) for its flagship drug-eluting stent, Supraflex Cruz. This approval enables SMT to expand into the highly regulated Australian market, highlighting India’s growing influence in the global medical device sector.

Kanchan Chauhan, Medical Devices Analyst at GlobalData, comments: “While drug eluting stents have significantly improved patient outcomes, treating tortuous and calcified lesions remains a challenge due to the complex structure of the vessels. Stents with enhanced flexibility, ultrathin struts, and lower crossing profiles are designed to address these challenges more effectively by reducing complications such as restenosis and promoting faster recovery. Increasing the availability of such advanced solutions is crucial for enhancing cardiovascular care.”

Supraflex Cruz delivers a combination of the sirolimus drug and a biodegradable polymer promoting faster vessel healing and reducing the risk of restenosis. The stent has been approved in over 80 countries, and with the recent TGA approval, it is set to be introduced in Australia, further solidifying its reputation for safety and efficacy.

Chauhan concludes: “As India continues to innovate in the cardiovascular space, the international success of devices such as Supraflex Cruz highlights the country’s growing presence in cardiovascular market. With increasing foreign interest and a developing domestic market, India has the potential to enhance its role in the global medical device industry.”